Lynda Spelman (L J Spelman, L Spelman)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Venues

The British journal of dermatology

The Australasian journal of dermatology

Case reports in obstetrics and gynecology

Clinical and translational science

Veracity Clinical Research Pty Ltd

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Veracity Clinical Research Pty Ltd Jul 01 2013

Australia

Director

Queensland Institute of Dermatology

Australia

Chairman/Director :: Dermatology

Specialist Connect - Nov 01 2017

Australia

Dermatologist

Publications

Saxon D Smith, Simon J Fifer, Meredith Edwards, Anne Walter, Yichen Zhong, Joe Zhuo, Bronwyn West, Lynda Spelman
Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia. The Journal of dermatological treatment 35 (1) (2024)
Junying Wang, Jeffery White, Kenneth J Sansone, Lynda Spelman, Rodney Sinclair, Xin Yang, Wubin Pan, Zheng Wei
Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clinical and translational science (2023)
Peter Foley, Yves A Kerdraon, John P Hogden, Stephen Shumack, Lynda Spelman, Deshan Frank Sebaratnam, Charles S Su, Constance H Katelaris
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting. The Australasian journal of dermatology 63 (4) (2022)
Andreas Wollenberg, Andrew Blauvelt, Emma Guttman-Yassky, Margitta Worm, C Lynde, Jean-Philippe Lacour, Lynda Spelman, Norito Katoh, Hidehisa Saeki, Y Poulin, A Lesiak, Leon Kircik, S H Cho, Pedro Herranz Pinto, Michael J Cork, Ketty Peris, L A Steffensen, B Bang, A Kuznetsova, T N Jensen, M L Østerdal, E L Simpson, null null
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). The British journal of dermatology 184 (3) (2020)
K M Darch, T L Holland, Lynda Spelman
Hidradenitis Suppurativa Recurrence in a Caesarean Scar. Case reports in obstetrics and gynecology 2020 (2020)
Robert Sinclair, Christopher Baker, Lynda Spelman, Madeleine Supranowicz, Beth MacMahon
A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies. The Australasian journal of dermatology 62 (2) (2020)
E L Simpson, J-P Lacour, Lynda Spelman, R Galimberti, L F Eichenfield, Robert Bissonnette, B A King, J P Thyssen, Jonathan Ian Silverberg, T Bieber, K Kabashima, Y Tsunemi, A Costanzo, Emma Guttman-Yassky, L A Beck, J M Janes, A M DeLozier, M Gamalo, D R Brinker, T Cardillo, F P Nunes, A S Paller, A Wollenberg, K Reich
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. The British journal of dermatology 183 (2) (2020)
Kim A Papp, C Maari, A Cauthen, Melinda J Gooderham, Lynda Spelman, Keiichi Yamanaka, P Polzer, L Zhang, O Osuntokun, Matthias Augustin
An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12. The British journal of dermatology 183 (1) (2019)

Lynda Spelman.css-eqlu8i{font-size:small;padding-left:4px;} (L J Spelman, L Spelman)

Publication Activity (10 Years)

Top Topics

Top Venues

Lynda Spelman (L J Spelman, L Spelman)